QBKPN SSI / Qu Biologics - LARVOL DELTA

RESILIENCE: Efficacy of QBKPN Site-Specific Immunomodulator in Improving Innate Immune Function & Reducing Respiratory Tract Infection in Older Adults (clinicaltrials.gov) - P2 | N=72 | Recruiting | Sponsor: Qu Biologics Inc. | Trial completion date: Jul 2025 ➔ Feb 2026 | Trial primary completion date: Jan 2025 ➔ Sep 2025

Trial completion date • Trial primary completion date • Infectious Disease • Respiratory Diseases • ALK • CD4 • CD8 • CRP

RESILIENCE: Efficacy of QBKPN Site-Specific Immunomodulator in Improving Innate Immune Function & Reducing Respiratory Tract Infection in Older Adults (clinicaltrials.gov) - P2 | N=72 | Recruiting | Sponsor: Qu Biologics Inc. | Active, not recruiting ➔ Recruiting | Trial completion date: Mar 2025 ➔ Jul 2025 | Trial primary completion date: Sep 2024 ➔ Jan 2025

Enrollment open • Immunomodulating • Trial completion date • Trial primary completion date • Infectious Disease • Respiratory Diseases • ALK • CD4 • CD8 • CRP

Tracking the fate of bacteria-derived site-specific immunomodulators by positron emission tomography. (PubMed, Nucl Med Biol) - "Radiolabeling of SSIs allows for longitudinal in vivo imaging of biodistribution and trafficking. PET imaging revealed differential biodistribution of the SSIs based on the organotropism of the bacteria from which the SSI is derived. Trafficking from the site of injection to the targeted site is in part mediated via the lymphatics and involves macrophages and neutrophils."

Immunomodulating • Journal • Chronic Obstructive Pulmonary Disease • Gastroenterology • Gastrointestinal Disorder • Immunology • Infectious Disease • Inflammatory Bowel Disease • Lung Cancer • Oncology • Pulmonary Disease • Respiratory Diseases • Solid Tumor

RESILIENCE: Assessment of QBKPN Site-Specific Immunomodulator Efficacy in Improving Innate Immune Function & Reducing Respiratory Tract Infection Morbidity in Older Adults (clinicaltrials.gov) - P2 | N=72 | Active, not recruiting | Sponsor: Qu Biologics Inc. | Not yet recruiting ➔ Active, not recruiting | Trial completion date: Dec 2023 ➔ Mar 2025 | Trial primary completion date: Dec 2023 ➔ Sep 2024

Enrollment closed • Immunomodulating • Trial completion date • Trial primary completion date • Alzheimer's Disease • Infectious Disease • Respiratory Diseases • ALK • CRP • CSF2 • IFNG • IL1B

RESILIENCE: Assessment of QBKPN Site-Specific Immunomodulator Efficacy in Improving Innate Immune Function & Reducing Respiratory Tract Infection Morbidity in Older Adults (clinicaltrials.gov) - P2 | N=72 | Not yet recruiting | Sponsor: Qu Biologics Inc.

New P2 trial • Alzheimer's Disease • Immune Modulation • Immunology • Infectious Disease • Inflammation • Respiratory Diseases • ALK • CRP • CSF2 • IFNG • IL1B

Qu Biologics Receives Additional Funding to Accelerate Clinical Development of Qu’s First-in-Class Immunotherapeutic for COVID-19 Prevention and Treatment (GlobeNewswire) - "Qu Biologics Inc....is receiving advisory services and additional research and development funding of up to $1,971,195 funding from the National Research Council of Canada Industrial Research Assistance Program (NRC IRAP) to quickly move forward the application of Qu’s lung-directed SSI, QBKPN, to prevent and treat COVID-19....This new funding will further research and manufacturing, including confirmation that QBKPN protects against new COVID-19 variants, production of QBKPN SSI in Canada in preparation for a COVID-19 clinical trial, expansion of Qu’s research and development teams, and support for a COVID-19 clinical trial application regulatory submission and approval."

Financing • Infectious Disease • Novel Coronavirus Disease